Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ian M. Chalmers is active.

Publication


Featured researches published by Ian M. Chalmers.


Baillière's clinical rheumatology | 1996

The immune effects of neuropeptides

Istvan Berczi; Ian M. Chalmers; Eva Nagy; Richard Warrington

Current evidence indicates that the neuroendocrine system is the highest regulator of immune/inflammatory reactions. Prolactin and growth hormone stimulate the production of leukocytes, including lymphocytes, and maintain immunocompetence. The hypothalamus-pituitary-adrenal axis constitutes the most powerful circuit regulating the immune system. The neuropeptides constituting this axis, namely corticotrophin releasing factor, adrenocorticotrophic hormone, alpha-melanocyte stimulating hormone, and beta-endorphin are powerful immunoregulators, which have a direct regulatory effect on lymphoid cells, regulating immune reactions by the stimulation of immunoregulatory hormones (glucocorticoids) and also by acting on the central nervous system which in turn generates immunoregulatory nerve impulses. Peptidergic nerves are major regulators of the inflammatory response. Substance P and calcitonin gene-related peptide are pro-inflammatory mediators and somatostatin is anti-inflammatory. The neuroendocrine regulation of the inflammatory response is of major significance from the point of view of immune homeostasis. Malfunction of this circuit leads to disease and often is life-threatening. The immune system emits signals towards the neuroendocrine system by cytokine mediators which reach significant blood levels (cytokine-hormones) during systemic immune/inflammatory reactions. Interleukin-1, -6, and TNF-alpha are the major cytokine hormones mediating the acute phase response. These cytokines induce profound neuroendocrine and metabolic changes by interacting with the central nervous system and with many other organs and tissues in the body. Corticotrophin releasing factor functions under these conditions as a major co-ordinator of the response and is responsible for activating the ACTH-adrenal axis for regulating fever and for other CNS effects leading to a sympathetic outflow. Increased ACTH secretion leads to glucocorticoid production. alpha-melanocyte stimulating hormone functions under these conditions as a cytokine antagonist and an anti-pyretic hormone. The sympathetic outflow, in conjunction with increased adrenal activity. leads to the elevation of catecholamines in the bloodstream and in tissues. Current evidence suggests that neuroimmune mechanisms are essential in normal physiology, such as tissue turnover, involution, atrophy, intestinal function, and reproduction. Host defence against infection, trauma and shock relies heavily on the neuroimmunoregulatory network. Moreover, abnormalities of neuroimmunoregulation contribute to the aetiology of autoimmune disease, chronic inflammatory disease, immunodeficiency, allergy, and asthma. Finally, neuroimmune mechanisms play an important role in regeneration and healing.


Autoimmunity | 1993

Hormones in self Tolerance and Autoimmunity: A role in the Pathogenesis of Rheumatoid Arthritis?

Istvan Berczi; Fletcher Baragar; Ian M. Chalmers; Edward C. Keystone; Eva Nagy; Richard Warrington

Recent studies indicate that pituitary hormones play an important role in immunoregulation. The evidence that endocrine abnormalities are associated with, and may contribute to the development of autoimmune disease is reviewed and discussed. Patients suffering from rheumatoid arthritis show a number of endocrine abnormalities that indicate altered pituitary function. The decreased bioactivity of prolactin and possible inadequate glucocorticoid response to inflammation found in patients may have an etiological role in rheumatoid arthritis. The further clarification of the possible role of endocrine factors in the etiology of autoimmune disease is needed urgently.


Arthritis & Rheumatism | 2001

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

Janet E. Pope; Nicholas Bellamy; James R. Seibold; Murray Baron; Michael H. Ellman; Simon Carette; C. Douglas Smith; Ian M. Chalmers; Paul Hong; David P. O'Hanlon; Elzbieta Kaminska; Janet Markland; John Sibley; Luis J. Catoggio; Daniel E. Furst


The Journal of Rheumatology | 1995

Variability of skin scores and clinical measurements in scleroderma.

Janet E. Pope; Baron M; Bellamy N; Campbell J; Simon Carette; Ian M. Chalmers; Dales P; John G. Hanly; Elzbieta Kaminska; Peter Lee


The Journal of Rheumatology | 1991

Prolactin deficiency in rheumatoid arthritis.

Eva Nagy; Ian M. Chalmers; Fletcher Baragar; H. G. Friesen; Istvan Berczi


Arthritis & Rheumatism | 1986

Rheumatic diseases in an inuit population

Kiem Oen; Brian Postl; Ian M. Chalmers; Norma Ling; Maria Louise Schroeder; Fletcher Baragar; Liam Martin; Martin H. Reed; Paul Major


Rheumatology | 2004

The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma

N. Sultan; Janet E. Pope; P. Clements; D.E. Furst; J. R. Siebold; Weng Kee Wong; Bellamy N; Maureen D. Mayes; Baron M; Bruce A. White; Michael H. Ellman; Fredrick M. Wigley; Simon Carette; M. H. Weismann; C. D. Smith; Walter G. Barr; Ian M. Chalmers; L. W. Moreland; Thomas A. Medsger; Paul Hong; Virginia Steen; David P. O'Hanlon; Richard W. Martin; Elzbieta Kaminska; David H. Collier; Janet Markland; Edward V. Lally; John Sibley; John Varga; Luis J. Catoggio


The Journal of Rheumatology | 1990

A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status.

Ian M. Chalmers; Sitar Ds; Hunter T


The Journal of Rheumatology | 1985

Measurements of maximum respiratory pressures in polymyositis and dermatomyositis.

Martin L; Ian M. Chalmers; Dhingra S; McCarthy D; Hunter T


The Journal of Rheumatology | 1985

Sulfasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity.

Martin L; Sitar Ds; Ian M. Chalmers; Hunter T

Collaboration


Dive into the Ian M. Chalmers's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eva Nagy

University of Manitoba

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Janet E. Pope

University of Western Ontario

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Baron M

University of Western Ontario

View shared research outputs
Top Co-Authors

Avatar

Bellamy N

London Health Sciences Centre

View shared research outputs
Top Co-Authors

Avatar

David P. O'Hanlon

University of British Columbia

View shared research outputs
Researchain Logo
Decentralizing Knowledge